Sagimet biosciences to present at the h.c. wainwright 8th annual mash virtual conference and announces inducement grants under nasdaq listing rule 5635(c)(4)

San mateo, calif., oct. 01, 2024 (globe newswire) -- sagimet biosciences inc. (sagimet, nasdaq: sgmt), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (fasn) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a virtual fireside chat at the h.c. wainwright 8th annual mash virtual conference at 2:30 pm et on monday, october 7, 2024.
NDAQ Ratings Summary
NDAQ Quant Ranking